Clinical Trial Detail

NCT ID NCT02658019
Title Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lynn Feun
Indications

hepatocellular carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.